![]() |
市場調查報告書
商品編碼
1468258
2024-2032 年癌症惡病質市場報告(依治療方法、作用方式、配銷通路和地區)Cancer Cachexia Market Report by Therapeutics, Mode of Action, Distribution Channel, and Region 2024-2032 |
IMARC Group年,全球癌症惡病質市場規模達21億美元。
癌症惡病質是指多因素的宿主吞噬消耗症候群,其特徵是系統性發炎、無意識的瘦體重損失、蛋白質負平衡、食慾不振和肌肉萎縮。它是由多種慢性疾病的發生引起的,包括結核病(TB)、多發性硬化症、慢性阻塞性肺病(COPD)和人類免疫缺陷病毒(HIV)。癌症惡病質可以使用多種療法來治療,例如黃體素、皮質類固醇和聯合療法。其中,黃體素是一種合成或天然類固醇激素,可改善食慾並促進體重增加,而皮質類固醇有助於減輕發炎和抑制過度活躍的免疫系統。
癌症和惡病質的盛行率不斷增加,特別是在不斷增加的老年人口中,促進了對先進治療方法和藥物的需求,這反過來又主要推動了市場的成長。消費者對治療癌症惡病質的新型治療藥物的可用性的認知不斷提高,進一步支持了這一點。此外,患者轉向透過藥物、非藥物治療和臨床試驗改善去脂體重(LBM)的聯合治療的傾向正在成為另一個生長誘導因素。與此一致的是,用於改善消化的多種食慾興奮劑(例如醋酸甲地孕酮、地塞米松和甲基強的松龍)的廣泛使用也促進了市場的成長。此外,強調開發治療癌症惡病質的有效藥物的重大技術進步進一步推動了市場成長。除此之外,各國政府機構和非政府組織(NGO)採取了許多有利舉措,提高人們對癌症惡病質的原因、症狀和使用先進治療的好處的認知,這為癌症惡病質的發展創造了積極的前景。
The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer cachexia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutics, mode of action and distribution channel.
Progestogens
Corticosteroids
Combination Therapy
Others
Appetite Stimulators
Weight Loss Stabilizers
Hospital Stores
Retail Pharmacy
Online Pharmacy
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.